We sought to determine the significance of minimal residual disease (MRD) relapse in patients with ALL after achieving MRD negative status following induction and consolidation therapy. 16 continued maintenance chemotherapy; 15 received late intensification; 9 allogeneic stem cell transplant, 9 changed chemotherapy, 6 no further therapy. Only six remain alive and in CR1 and nine are alive after morphological relapse. MRD relapse detected by MFC at any time after achieving CR is associated with a high risk for morphological relapse. SCT can result in long-term remission in some patients. Prospective studies of long-term MRD assessments, together with less toxic treatment strategies to eradicate MRD, are warranted.
| I N T R O D U C T I O N
The assessment of minimal residual disease (MRD) at the end of induction chemotherapy has been established as one of the most important independent predictors of patient outcomes in pediatric and adult ALL, and is becoming a key component of therapeutic decision making in modern ALL treatment regimens. [1] [2] [3] [4] [5] New techniques for the detection of MRD in various leukemia subtypes have been developed and are being refined and validated. These techniques are aimed at recognition of submicroscopic disease persistence or recurrence and for potential early therapeutic intervention. [6] [7] [8] [9] [10] [11] Multi-parameter flow cytometry (MFC) has been used extensively in pediatric and, more recently, adult ALL studies, to determine the likelihood of relapse and overall success of therapy. [6] [7] [8] 12, 13 From 2004, we have routinely and systematically evaluated the presence of MRD using flow cytometry in bone marrow specimens obtained from patients with ALL treated on various clinical trials at our institution. 3, 14, 15 While the role of MRD assessment and significance of achieving MRD negativity as assessed specifically by MFC at the end of induction and consolidation have been evaluated in previous studies including the adult ALL population, 3, 5 there is limited existing data on the significance of MRD recurrence in the absence of morphological relapse and whether it is universally associated with a poor outcome.
Herein, we aim to determine the significance of MRD relapse, as detected by MFC, in adult patients with ALL after achieving MRD negativity, following induction and consolidation therapy. Augmented BFM, with the specific details of each program reported previously. 16, 17 Table 1 describes pre-treatment patient characteristics and presents a comparison of the patients in the study group (n 5 55) versus those with persistent MRD negativity CR (n 5 491). There were no significant differences found among the two groups in terms of pretreatment characteristics. 
| Statistical definitions
Overall survival (OS) was defined as the time interval from the time of MRD relapse and the date of death due to any cause. Patients who were alive were censored at the last follow-up date. Diseasefree survival (DFS) was defined as the time interval between date of MRD relapse and the date of disease relapse, or death due to any cause, whichever event occurred first. Time to relapse was defined as the time interval between date of MRD relapse and the date of disease relapse (death before disease relapse was denoted as a censored event). The probabilities of OS, DFS, and time to relapse were estimated using the method of Kaplan and Meier, 19 and the log-rank test 20 was performed to assess differences between patients with MRD positive versus negative status.
Statistical analyses were conducted in SAS 9.3 and Splus (SAS Institute, Cary, NC). 
| R E S U LTS
Among 647 patients diagnosed with ALL during the study period (Janu- 
| DISCUSSION
Although improvements in overall survival among all subgroups of adults with ALL have not yet matched those achieved in the pediatric ALL patient population, 21 there have been several significant developments over the past decade leading to improved outcomes for adult patients. 22 These include the introduction of novel targeted therapies, 22 expanding experience with the use of stem cell transplantation, 23, 24 and better risk stratification and individualized therapeutic choices. 13, 22, 25 Furthermore, the recent development of targeted monoclonal antibody-based strategies, has created new opportunities, including the potential for therapy in patients with MRD positive disease. 26, 27 Blinatumomab, a bi-specific T-cell engager antibody, which was initially studied in the MRD positive ALL setting, recently attained FDA approval in the United States for the treatment of patients with relapsed/refractory Philadelphia negative B-ALL. 28 Because MRD detection is strongly associated with worse outcomes in patients with ALL, specific targeting for elimination of MRD remains an urgent, unmet need. Ample available data has established MRD detection at the end of induction and consolidation, as well as pre-and post-SCT, as an independent poor prognostic parameter among patients with ALL of all age groups, including pediatric, adolescent and young adult (AYA), and adult populations. 3, 5, 6, 12, 17, 29, 30 In this analysis, among 546 patients with ALL who achieved an MRD negative patients. 12 According to this large retrospective analysis at a major SCT center, detection of MRD prior to SCT is a significant risk for transplant failure. 12 These findings again highlight the need not only for serial assessment of MRD, but also the urgent need for novel, less toxic strategies, and enrollment on clinical trials specifically designed for patients with ALL and MRD persistence/recurrence.
One limitation of the current retrospective study is the lack of predetermined, standard time points during long-term follow-up and after induction and consolidation for uniform MRD assessments. Regardless, we demonstrate in this analysis that MRD recurrence at any time after
induction and consolidation appears to be a harbinger of morphological relapse, and therefore therapy to eradicate MRD should be considered In this single institution retrospective analysis, the vast majority of patients with ALL who achieved MRD negative CR followed by MRD relapse, subsequently experienced morphological relapse, which suggests that MRD relapse at any time point during a patient's follow-up is associated with a high risk for morphological relapse. Although allogeneic SCT rescued some patients with ongoing long-term remission, it was associated with mortality in others. Prospective studies of longterm, serial MRD assessments throughout a patient's treatment course and follow-up, coupled with less toxic strategies designed to eradicate MRD represent an ongoing, urgent area of unmet medical need for adult patients with ALL.
DISCLOSURES/CONFLICTS OF I NTEREST
The authors have no conflicts of interest to disclose with regards to this manuscript. 
AUTHORS HIP CONTRIBUTIONS

